



Preliminary review of menstrual blood-derived cell therapy to support astronauts in long-term space missions

Marion Dugué – TU Delft, MSc student







OUTLINE

Motivation

Pipeline

Key facts > Naïve calculations

Future research



MOTIVATION

+.

.



WASTE

RESOURCE



PIPELINE

į





2. Transfer to onboard lab



Collection of fluid

3. Isolation of MenSC

- 4. Cultivation/proliferation
- 5. (Optional) Storage



6. Injection





WHAT WE KNOW

+ .

.



Mesenchymal stem cells

Embryonic stem cells

Menstrual-blood derived stem cells (MenSC):

- Plastic adherent
- Don't express class II histocompatibility complex (MHC)
- Duplication rate (on Earth) of 19.4h



Menstrual blood key facts

Menstruating astronauts
35 years old average

Duration

Average periods during 5-7 days for a cycle of around 28 days

Quantity
60ml of menstrual fluid per period



MenSC/Stem cell key facts

- Content
 - 600 CFU-F per ml of menstrual fluid
- Duplication rate of MenSC 19.4h
- Injection requirements
 - Local injection
 - ~20 to 50 million stem cells
 - IV injection
 - \sim 70 to 190 million.



Cell count from one menstruation cycle as a function of days



NAIVE CALCULATIONS



Assumption #1:

Periods in space are analog to those on Earth

Assumption #2:

Microgravity cell mechanisms analog to those on Earth

Assumption #3:

Stem cell therapy is appropriate for crewed missions



IS IT FEASIBLE?



Insights from this prelim. review

- Naively, quantities and timeframe
- More research needed
 - Periods in micro-gravity (quantity, quality but also comfort and psychology of the menstruating astronauts)
 - MenSC mechanisms in space
 - Development of required apparatus (e.g micro-gravity menstrual cup, isolation of MenSC)



THANK YOU.

Marion Dugué

marion-dugue@live.fr https://www.linkedin.com/in/mariondugue/

www.melissafoundation.org

Follow us on social networks











PARTNERS































